These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33261044)

  • 1. Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.
    Igreja Sá IC; Tripska K; Hroch M; Hyspler R; Ticha A; Lastuvkova H; Schreiberova J; Dolezelova E; Eissazadeh S; Vitverova B; Najmanova I; Vasinova M; Pericacho M; Micuda S; Nachtigal P
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice.
    Dolezelova E; Sa ICI; Prasnicka A; Hroch M; Hyspler R; Ticha A; Lastuvkova H; Cermanova J; Pericacho M; Visek J; Lasticova M; Micuda S; Nachtigal P
    Life Sci; 2019 Sep; 232():116643. PubMed ID: 31299237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts.
    Vitverova B; Najmanova I; Vicen M; Tripska K; Sa ICI; Hyspler R; Pericacho M; Nachtigal P
    PLoS One; 2020; 15(5):e0233725. PubMed ID: 32470058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Levels of Soluble Endoglin Induce a Proinflammatory and Oxidative-Stress Phenotype Associated with Preserved NO-Dependent Vasodilatation in Aortas from Mice Fed a High-Fat Diet.
    Jezkova K; Rathouska J; Nemeckova I; Fikrova P; Dolezelova E; Varejckova M; Vitverova B; Tysonova K; Serwadczak A; Buczek E; Bernabeu C; Lopez-Novoa JM; Chlopicki S; Nachtigal P
    J Vasc Res; 2016; 53(3-4):149-162. PubMed ID: 27721318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
    Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes.
    Schumacher-Petersen C; Christoffersen BØ; Kirk RK; Ludvigsen TP; Zois NE; Pedersen HD; Vyberg M; Olsen LH
    J Transl Med; 2019 Apr; 17(1):110. PubMed ID: 30943987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Vitverova B; Blazickova K; Najmanova I; Vicen M; Hyšpler R; Dolezelova E; Nemeckova I; Tebbens JD; Bernabeu C; Pericacho M; Nachtigal P
    Atherosclerosis; 2018 Apr; 271():15-25. PubMed ID: 29459262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo.
    Eissazadeh S; Mohammadi S; Faradonbeh FA; Rathouska JU; Nemeckova I; Tripska K; Vitverova B; Dohnalkova E; Vasinova M; Fikrova P; Sa ICI; Micuda S; Nachtigal P
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166990. PubMed ID: 38110128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.
    Suga T; Yamaguchi H; Ogura J; Shoji S; Maekawa M; Mano N
    Toxicol Appl Pharmacol; 2019 Sep; 379():114664. PubMed ID: 31306673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
    Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
    World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
    Lastuvkova H; Faradonbeh FA; Schreiberova J; Hroch M; Mokry J; Faistova H; Nova Z; Hyspler R; Igreja Sa IC; Nachtigal P; Stefela A; Pavek P; Micuda S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol Induces Nrf-2- and HIF-1
    Kaminsky-Kolesnikov Y; Rauchbach E; Abu-Halaka D; Hahn M; García-Ruiz C; Fernandez-Checa JC; Madar Z; Tirosh O
    Oxid Med Cell Longev; 2020; 2020():5393761. PubMed ID: 32566088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High soluble endoglin levels do not induce changes in structural parameters of mouse heart.
    Rathouska J; Fikrova P; Mrkvicova A; Blazickova K; Varejckova M; Dolezelova E; Nemeckova I; Vitverova B; Peslova L; Gallardo-Vara E; Pericacho M; Nachtigal P
    Heart Vessels; 2017 Aug; 32(8):1013-1024. PubMed ID: 28382387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
    Kumar S; Verma AK; Rani R; Sharma A; Wang J; Shah SA; Behari J; Salazar Gonzalez R; Kohli R; Gandhi CR
    Hepatology; 2020 Nov; 72(5):1586-1604. PubMed ID: 32031683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
    Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
    Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
    Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.